JP2010514455A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010514455A5 JP2010514455A5 JP2009544412A JP2009544412A JP2010514455A5 JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5 JP 2009544412 A JP2009544412 A JP 2009544412A JP 2009544412 A JP2009544412 A JP 2009544412A JP 2010514455 A5 JP2010514455 A5 JP 2010514455A5
- Authority
- JP
- Japan
- Prior art keywords
- lymphocytes
- composition
- antigen
- composition according
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 210000004698 Lymphocytes Anatomy 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 102000038129 antigens Human genes 0.000 claims 8
- 108091007172 antigens Proteins 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 210000000400 T-Lymphocytes, Cytotoxic Anatomy 0.000 claims 4
- 210000004027 cells Anatomy 0.000 claims 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 4
- 230000035131 DNA demethylation Effects 0.000 claims 3
- 210000004443 Dendritic Cells Anatomy 0.000 claims 3
- 238000006640 acetylation reaction Methods 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 210000000612 Antigen-Presenting Cells Anatomy 0.000 claims 2
- 210000004369 Blood Anatomy 0.000 claims 2
- 210000001550 Testis Anatomy 0.000 claims 2
- 230000003698 anagen phase Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001472 cytotoxic Effects 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 230000004936 stimulating Effects 0.000 claims 2
- 229960005486 vaccines Drugs 0.000 claims 2
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 1
- 230000003213 activating Effects 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003381 deacetylation reaction Methods 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
Claims (17)
- 成熟樹状細胞による活性化の後に、癌/精巣抗原の発現をDNA脱メチル化又はヒストンアセチル化により化学的に誘導しているリンパ細胞を含む、哺乳動物において免疫応答を誘導する組成物。
- 前記リンパ細胞がリンパ球である、請求項1に記載の組成物。
- 前記リンパ球が末梢血リンパ球である、請求項2に記載の組成物。
- 前記抗原は対数増殖期に誘導されている、請求項1〜3のいずれか一項に記載の組成物。
- 前記抗原発現リンパ球がCD4+細胞を含む、請求項2〜4のいずれか一項に記載の組成物。
- 前記DNA脱メチル化が、5-アザ-2-デオキシシチジンによる処理を含む、請求項1〜5のいずれか一項に記載の組成物。
- 前記ヒストンアセチル化が、ヒストン脱アセチル化インヒビターによる処理を含む、請求項1〜5のいずれか一項に記載の組成物。
- 請求項1〜7のいずれか一項に記載の組成物と、許容可能な担体とを含む、予防処置又は治療処置用のワクチン。
- 前記腫瘍抗原に対する免疫応答を刺激するワクチンを調製するための請求項1〜7のいずれか一項に記載の組成物の使用。
- 細胞傷害性Tリンパ球を活性化する抗原提示細胞としての請求項1〜7のいずれか一項に記載の組成物の使用。
- 抗原提示細胞として請求項1〜7のいずれか一項に記載の組成物を使用して、Tリンパ球を活性化することを含む、腫瘍特異的CD8+細胞傷害性Tリンパ球を製造する方法。
- 養子T細胞免疫療法用の医薬組成物を調製するための、請求項11に記載の方法によって得られた腫瘍特異的CD8+細胞傷害性Tリンパ球の使用。
- 成熟樹状細胞を使用して正常な非活性化リンパ細胞の増殖を刺激すること、及びDNA脱メチル化又はヒストンアセチル化を誘導する作用物質で増殖細胞を化学処理して癌/精巣抗原の発現を誘導することを含む、CD4+細胞が豊富な抗原提示組成物を製造する方法。
- 前記リンパ細胞が、他家血液又は自己血液から抽出した末梢血リンパ球である請求項13に記載の方法。
- 前記抗原は対数増殖期に誘導されている請求項13又は14に記載の方法。
- 請求項13〜15のいずれか一項に記載の方法で抗原提示組成物を調製すること、及び該抗原提示組成物を使用して、T細胞リンパ球を活性化させ、それにより腫瘍特異的CD8+細胞傷害性Tリンパ球を含有する細胞傷害性組成物を得ることを含む、細胞傷害性組成物を製造する方法。
- T細胞リンパ球の数が、成熟樹状細胞の使用による活性化の後に増える請求項16に記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0700058.1 | 2007-01-03 | ||
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
| PCT/EP2008/050050 WO2008081035A1 (en) | 2007-01-03 | 2008-01-03 | Anti-tumor vaccine derived from normal chemically modified cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010514455A JP2010514455A (ja) | 2010-05-06 |
| JP2010514455A5 true JP2010514455A5 (ja) | 2012-10-25 |
| JP5452231B2 JP5452231B2 (ja) | 2014-03-26 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009544412A Expired - Fee Related JP5452231B2 (ja) | 2007-01-03 | 2008-01-03 | 化学的に修飾した正常な細胞由来の抗腫瘍ワクチン |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (ja) |
| EP (1) | EP2102331B1 (ja) |
| JP (1) | JP5452231B2 (ja) |
| AT (1) | ATE522600T1 (ja) |
| AU (1) | AU2008203730B2 (ja) |
| CY (1) | CY1112668T1 (ja) |
| DK (1) | DK2102331T3 (ja) |
| ES (1) | ES2372713T3 (ja) |
| GB (1) | GB0700058D0 (ja) |
| HR (1) | HRP20110899T1 (ja) |
| PL (1) | PL2102331T3 (ja) |
| PT (1) | PT2102331E (ja) |
| SI (1) | SI2102331T1 (ja) |
| WO (1) | WO2008081035A1 (ja) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8586359B2 (en) * | 2009-07-28 | 2013-11-19 | Promising Furture, LLC | Compositions and methods of preparing alloreactive cytotoxic T cells |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| EP2494038B1 (en) | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| IL295224A (en) | 2015-05-28 | 2022-10-01 | Kite Pharma Inc | Methods for training patients for t-cell therapy |
| MA45281A (fr) | 2015-05-28 | 2018-04-11 | Kite Pharma Inc | Procédés de diagnostic pour thérapie par lymphocytes t |
| CN108366995A (zh) | 2015-10-20 | 2018-08-03 | 凯德药业股份有限公司 | 制备用于t细胞疗法的t细胞的方法 |
| WO2017173384A1 (en) | 2016-04-01 | 2017-10-05 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| KR102522622B1 (ko) | 2016-04-01 | 2023-04-18 | 카이트 파마 인코포레이티드 | Bcma 결합 분자 및 그의 사용 방법 |
| SG11201808411RA (en) | 2016-04-01 | 2018-10-30 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
| US11046775B2 (en) | 2017-02-14 | 2021-06-29 | Kite Pharma, Inc. | CD70 binding molecules and methods of use thereof |
| TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
| JP6748221B2 (ja) | 2017-04-01 | 2020-08-26 | エーブイエム・バイオテクノロジー・エルエルシー | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
| WO2018187332A1 (en) | 2017-04-03 | 2018-10-11 | Kite Pharma, Inc. | Treatment using chimeric receptor t cells incorporating optimized polyfunctional t cells |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| WO2018218105A1 (en) | 2017-05-26 | 2018-11-29 | Kite Pharma, Inc. | Methods of making and using embryonic mesenchymal progenitor cells |
| CN114533863A (zh) | 2017-09-15 | 2022-05-27 | 凯德药业股份有限公司 | 用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统 |
| WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
| CN111479613A (zh) | 2017-10-18 | 2020-07-31 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| KR20200110356A (ko) | 2018-01-15 | 2020-09-23 | 화이자 인코포레이티드 | 키메라 항원 수용체 면역요법을 4-1bb 효능제와 조합하여 투여하는 방법 |
| US20200390814A1 (en) | 2018-02-02 | 2020-12-17 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| WO2019161271A1 (en) | 2018-02-16 | 2019-08-22 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| CN112218888A (zh) | 2018-04-12 | 2021-01-12 | 凯德药业股份有限公司 | 使用肿瘤微环境的特征的嵌合受体t细胞治疗 |
| SG11202011541SA (en) | 2018-06-01 | 2020-12-30 | Kite Pharma Inc | Chimeric antigen receptor t cell therapy |
| EP3810780A1 (en) | 2018-06-22 | 2021-04-28 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| US20200038442A1 (en) | 2018-08-02 | 2020-02-06 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| US11793834B2 (en) | 2018-12-12 | 2023-10-24 | Kite Pharma, Inc. | Chimeric antigen and T cell receptors and methods of use |
| EP3953454A1 (en) | 2019-04-12 | 2022-02-16 | CytoVac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| BR112021021996A2 (pt) | 2019-05-03 | 2022-01-11 | Kite Pharma Inc | Métodos para administração de imunoterapia com receptores de antígeno quimérico |
| BR112021025735A2 (pt) | 2019-06-21 | 2022-03-08 | Kite Pharma Inc | Receptores de tgf-ss e métodos de uso |
| CN114341348A (zh) | 2019-09-03 | 2022-04-12 | 艾洛基治疗公司 | 制备用于t细胞疗法的t细胞的方法 |
| WO2021260675A1 (en) | 2020-06-24 | 2021-12-30 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| JP2023538012A (ja) | 2020-08-14 | 2023-09-06 | カイト ファーマ インコーポレイテッド | 免疫細胞機能の改善 |
| EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
| WO2022093925A1 (en) | 2020-10-28 | 2022-05-05 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| EP4267623A1 (en) | 2020-12-24 | 2023-11-01 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| CN116917737A (zh) | 2021-01-10 | 2023-10-20 | 凯德药业股份有限公司 | T细胞疗法 |
| WO2022157288A1 (en) | 2021-01-21 | 2022-07-28 | Cytovac A/S | Method for t-cell expansion and related medical applications |
| TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| US20220289815A1 (en) | 2021-03-11 | 2022-09-15 | Kite Pharma, Inc. | Immune cell function |
| KR20230172002A (ko) | 2021-04-16 | 2023-12-21 | 카이트 파마 인코포레이티드 | Taci/bcma 이중 결합 분자 |
| US20220336087A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| US20220378830A1 (en) | 2021-05-14 | 2022-12-01 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| EP4347638A2 (en) | 2021-05-24 | 2024-04-10 | Kite Pharma, Inc. | Nkg2d-based chimeric antgen receptor |
| AU2022291365A1 (en) | 2021-06-08 | 2024-01-18 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| WO2023278553A1 (en) | 2021-07-01 | 2023-01-05 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
| EP4376876A1 (en) | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| CA3225306A1 (en) | 2021-07-30 | 2023-02-02 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| CN118103403A (zh) | 2021-10-18 | 2024-05-28 | 凯德药业股份有限公司 | 嵌合抗原受体的信号传导结构域 |
| WO2023159001A1 (en) | 2022-02-15 | 2023-08-24 | Kite Pharma, Inc. | Predicting adverse events from immunotherapy |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| WO2024044670A1 (en) | 2022-08-26 | 2024-02-29 | Kite Pharma, Inc. | Improving immune cell function |
| WO2024092152A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Improving efficacy and durable response of immunotherapy |
| US20240158869A1 (en) | 2022-10-28 | 2024-05-16 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en active Application Filing
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
- 2011-11-30 HR HR20110899T patent/HRP20110899T1/hr unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010514455A5 (ja) | ||
| HRP20110899T1 (hr) | Protutumorsko cjepivo dobiveno iz normalnih, kemijski modificiranih stanica cd4+ | |
| Seledtsov et al. | Clinically feasible approaches to potentiating cancer cell-based immunotherapies | |
| JP6134763B2 (ja) | ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| Vicari et al. | Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse | |
| AU2003203051B2 (en) | Cancer therapy | |
| JP2015512866A5 (ja) | ||
| Taniguchi et al. | Discovery of NKT cells and development of NKT cell-targeted anti-tumor immunotherapy | |
| JP2013535218A5 (ja) | ||
| JP2013177430A5 (ja) | ||
| Ning et al. | β‐Glucan restores tumor‐educated dendritic cell maturation to enhance antitumor immune responses | |
| Park et al. | Dendritic cell-mediated cancer immunotherapy with Ecklonia cava fucoidan | |
| Huarte et al. | Ex vivo expansion of tumor specific lymphocytes with IL-15 and IL-21 for adoptive immunotherapy in melanoma | |
| Kobayashi et al. | Fever-range whole-body heat treatment stimulates antigen-specific T-cell responses in humans | |
| JP2014533938A5 (ja) | ||
| Kogo et al. | Suppression of murine tumour growth through CD 8+ cytotoxic T lymphocytes via activated DEC‐205+ dendritic cells by sequential administration of α‐galactosylceramide in vivo | |
| He et al. | Antigenicity and adjuvanticity co-reinforced personalized cell vaccines based on self-adjuvanted hydrogel for post-surgical cancer vaccination | |
| JP2010265327A (ja) | 癌抗原非特異的な標的化ｔ細胞の製造方法及び医薬 | |
| Gritzapis et al. | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice | |
| Choi et al. | The function of memory CD8+ T cells in immunotherapy for human diseases | |
| Liseth et al. | Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience | |
| Al Saihati | Overview of Dendritic Cell Vaccines as Effective Approaches in Cancer Immunotherapy. | |
| Delluc et al. | DC-based vaccine loaded with acid-eluted peptides in acute myeloid leukemia: the importance of choosing the best elution method | |
| Tripp et al. | Glycolipids injected into the skin are presented to NKT cells in the draining lymph node independently of migratory skin dendritic cells | |
| Peng et al. | EWS/FLI-l peptide-pulsed dendritic cells induces the antitumor immunity in a murine Ewing's sarcoma cell model |